Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | KIT | P10721 | 3/20 | 0.38 |
| ▸ | BCR | P11274 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 7/20 | 0.36 |
| ▸ | IGF1R | P08069 | 6/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.36 |
| ▸ | ABL2 | P42684 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086710 | 0.88 | JAK2 (0.38) | AURKAIGF1RAURKBIKBKBCHUK | |
| SCHEMBL23906589 | 0.88 | JAK2 (0.38) | AURKAIGF1RAURKBIKBKBCHUK | |
| SCHEMBL30086514 | 0.86 | ABL1 (0.38) | ABL1KITBCRLRRK2AURKA | |
| SCHEMBL25221131 | 0.86 | ABL1 (0.38) | ABL1KITBCRLRRK2AURKA | |
| SCHEMBL23906904 | 0.83 | ABL1 (0.40) | ABL1KITBCRAURKAIGF1R | |
| SCHEMBL23906210 | 0.83 | JAK2 (0.44) | ABL1BCRAURKAAURKB | |
| SCHEMBL25703588 | 0.83 | ABL1 (0.39) | ABL1KITBCRLRRK2AURKA | |
| SCHEMBL25703675 | 0.83 | ABL1 (0.39) | ABL1KITBCRLRRK2AURKA | |
| SCHEMBL30086466 | 0.82 | PLK4 (0.49) | ABL1KITBCRLRRK2ABL2 | |
| SCHEMBL23906234 | 0.82 | PLK4 (0.49) | ABL1KITBCRLRRK2ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | ABL1 124/4885KIT 58/4885BCR 447/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | ABL1 124/4885KIT 58/4885BCR 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.